(Q28266198)

https://api.crossref.org/works/10.1517%2F13543784.2012.685651

The efficacy of disulfiram for the treatment of alcohol use disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.685651

Opioid modulators for alcohol dependence.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.685651

Acamprosate for treatment of alcohol dependence: mechanisms, efficacy, and clinical utility

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.685651

Nalmefene for treatment of alcohol dependence

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.685651

Prediction of serotonergic treatment efficacy using age of onset and Type A/B typologies of alcoholism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.685651

Review of topiramate: an antiepileptic for the treatment of alcohol dependence

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.685651

Safety and efficacy of baclofen in the treatment of alcohol-dependent patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.685651

Efficacy and safety of aripiprazole in alcohol dependence.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.685651

Aripiprazole in the treatment of patients with alcohol dependence: a double-blind, comparison trial vs. naltrexone

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.685651

Pregabalin for the treatment of generalised anxiety disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.685651

Pregabalin: its efficacy, safety and tolerability profile in generalized anxiety

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.685651

Pregabalin for the treatment of generalized anxiety disorder: a novel pharmacologic intervention

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.685651

World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and post-traumatic stress disorders - first revision

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.685651

Ca2+ channel alpha2delta ligands: novel modulators of neurotransmission

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.685651

Pregabalin is a potent and selective ligand for α(2)δ-1 and α(2)δ-2 calcium channel subunits

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.685651

Feeling anxious: anticipatory amygdalo-insular response predicts the feeling of anxious anticipation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.685651

Pregabalin influences insula and amygdala activation during anticipation of emotional images.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.685651

Anxiolytic profile of pregabalin on elicited hippocampal theta oscillation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.685651

Pregabalin: From molecule to medicine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.685651

Pregabalin: a new neuromodulator with broad therapeutic indications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.685651

Pregabalin is effective against behavioral and electrographic seizures during alcohol withdrawal.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.685651

Efficacy and safety of pregabalin in alcohol dependence

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.685651

Pregabalin versus naltrexone in alcohol dependence: a randomised, double-blind, comparison trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.685651

Pregabalin in outpatient detoxification of subjects with mild-to-moderate alcohol withdrawal syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.685651

Pregabalin, tiapride and lorazepam in alcohol withdrawal syndrome: a multi-centre, randomized, single-blind comparison trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.685651

Pregabalin in benzodiazepine withdrawal

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.685651

Pregabalin in the discontinuation of long-term benzodiazepine use: a case-series

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.685651

Pregabalin in the discontinuation of long-term benzodiazepines' use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.685651

Effects of pregabalin on subjective sleep disturbance symptoms during withdrawal from long-term benzodiazepine use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.685651

Efficacy and tolerability of twice-daily pregabalin for treating pain and related sleep interference in postherpetic neuralgia: a 13-week, randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.685651

Metabolic considerations in a case of pregabalin-induced edema

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.685651

Pregabalin as a probable cause of acute liver injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.685651

Rash associated with pregabalin use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.685651

The adverse event profile of pregabalin: a systematic review and meta-analysis of randomized controlled trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.685651

Pregabalin treatment of anxiety in patients with substance use disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.685651

Pregabalin abuse, dependence, and withdrawal: a case report

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.685651

Yes, pregabalin can be abused!

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.685651

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.685651

Pregabalin and its potential for abuse

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.685651

Importance of cyberspace for the assessment of the drug abuse market: preliminary results from the Psychonaut 2002 project.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.685651

New trends in the cyber and street market of recreational drugs? The case of 2C-T-7 ('Blue Mystic').

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.685651

Is there a recreational misuse potential for pregabalin? Analysis of anecdotal online reports in comparison with related gabapentin and clonazepam data.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.685651

A signal for an abuse liability for pregabalin--results from the Swedish spontaneous adverse drug reaction reporting system

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.685651

Subjective, psychomotor, and physiological effects of pregabalin alone and in combination with oxycodone in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.685651

A double-blind, placebo- and positive-internal-controlled (alprazolam) investigation of the cognitive and psychomotor profile of pregabalin in healthy volunteers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.685651

Cognitive effects of pregabalin in healthy volunteers: a double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.685651